

Publications Dr Valerie Boige 2010-2019

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S. *EBioMedicine*. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

ROCK2 inhibition triggers the collective invasion of colorectal adenocarcinomas. Libanje F, Raingeaud J, Luan R, Thomas Z, Zajac O, Veiga J, Marisa L, Adam J, Boige V, Malka D, Goéré D, Hall A, Soazec JY, Prall F, Gelli M, Dartigues P, Jaulin F. *EMBO J*. 2019 Jul 15;38(14):e99299. doi: 10.15252/embj.201899299. Epub 2019 Jun 18.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J. *Gastric Cancer*. 2019 Jul 2. doi: 10.1007/s10120-019-00983-3. [Epub ahead of print]

Molecular targeted therapy of *BRAF*-mutant colorectal cancer. Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, Samallin E, Boige V, Malka D, Gelli M. *Ther Adv Med Oncol*. 2019 Jun 18;11:1758835919856494. doi: 10.1177/1758835919856494. eCollection 2019. Review.

Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. Boige V, Mollevi C, Gourgou S, Azria D, Seitz JF, Vincent M, Bigot L, Juzyna B, Miran I, Gerard JP, Laurent-Puig P. *Int J Cancer*. 2019 Dec 1;145(11):3163-3172. doi: 10.1002/ijc.32417. Epub 2019 May 31.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Philip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C; PRODIGE 9 Investigators and PRODIGE 20 Investigators. *Gut*. 2019 May 17. pii: gutjnl-2018-316407. doi: 10.1136/gutjnl-2018-316407. [Epub ahead of print]

Vision loss after chemotherapy: an irinotecan-induced retinopathy. Boilève A, Jozwiak M, Malka D, Boige V, Le Roy F, Paques M, Ducreux M. *Eur J Cancer*. 2019 May;112:80-82. doi: 10.1016/j.ejca.2019.02.015. Epub 2019 Apr 1. No abstract available.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, **Boige V**. *Br J Cancer*. 2019 Apr;120(9):896-902. doi: 10.1038/s41416-019-0443-4. Epub 2019 Apr 4.

Systemic treatment of pancreatic cancer revisited. Ducreux M, Seufferlein T, Van Laethem JL, Laurent-Puig P, Smolenschi C, Malka D, Boige V, Hollebecque A, Conroy T. *Semin Oncol*. 2019 Feb;46(1):28-38. doi: 10.1053/j.seminoncol.2018.12.003. Epub 2018 Dec 27. Review.

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973). Goéré D, Pignon JP, Gelli M, Elias D, Benhaim L, Deschamps F, Caramella C, Boige V, Ducreux M, de Baere T, Malka D. *BMC Cancer*. 2018 Aug 6;18(1):787. doi: 10.1186/s12885-018-4697-7.

Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect? Gelli M, Huguenin JFL, de Baere T, Benhaim L, Mariani A, Boige V, Malka D, Sourouille I, Ducreux M, Elias D, Goéré D. *Eur J Cancer*. 2018 Sep;100:94-103. doi: 10.1016/j.ejca.2018.04.015. Epub 2018 Jul 5.

Reply to M. Mo et al. Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bennouna J. *J Clin Oncol*. 2018 Aug 10;36(23):2452-2453. doi: 10.1200/JCO.2018.78.9669. Epub 2018 Jun 4. No abstract available.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF; for FFCD investigators. *Eur J Cancer*. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [*Eur J Cancer* 87 (2017) 122-130]. Verlingue L, Malka D, Allorant A, Massard C, Féré C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A. *Eur J Cancer*. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D, Taieb J, Selves J, Le Malicot K, Di Fiore F, Maillard E. *Dig Liver Dis*. 2018 Mar;50(3):305-307. doi: 10.1016/j.dld.2017.12.023. Epub 2017 Dec 30.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J; PRODIGE 9 Investigators. *J Clin Oncol*. 2018 Mar 1;36(7):674-681. doi: 10.1200/JCO.2017.75.2931. Epub 2018 Jan 18.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Verlingue L, Malka D, Allorant A, Massard C, Féré C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A. *Eur J Cancer*. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: *Eur J Cancer*. 2018 Feb 14;:.

First-line treatment in metastatic colorectal cancer: Important or crucial? Malka D, Rotolo F, **Boige V**. *Eur J Cancer*. 2017 Oct;84:363-366. doi: 10.1016/j.ejca.2017.09.001. No abstract available.

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Chebib R, Verlingue L, Cozic N, Faron M, Burtin P, Boige V, Hollebecque A, Malka D. *Semin Oncol*. 2017 Apr;44(2):114-128. doi: 10.1053/j.seminoncol.2017.07.004. Epub 2017 Aug 2. Review.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A. *J Natl Cancer Inst*. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx136.

Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. Le Roy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, Benhaim

L, Malka D, Ducreux M, Elias D, Goéré D. *Ann Surg Oncol*. 2017 Nov;24(12):3640-3646. doi: 10.1245/s10434-017-6033-x. Epub 2017 Aug 28.

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A. *Br J Cancer*. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17.

Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC. Roy P, Canet-Jourdan C, Annereau M, Zajac O, Gelli M, Broutin S, Mercier L, Paci A, Lemare F, Ducreux M, Elias D, Malka D, Boige V, Goéré D, Jaulin F. *Int J Pharm*. 2017 Oct 5;531(1):143-152. doi: 10.1016/j.ijpharm.2017.07.084. Epub 2017 Aug 11.

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground? Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Ferté C. *Eur J Cancer*. 2017 Aug;81:161-173. doi: 10.1016/j.ejca.2017.05.006. Epub 2017 Jun 17. Review.

The role of image-guided therapy in the management of colorectal cancer metastatic disease. de Baere T, Tselikas L, Yevich S, Boige V, Deschamps F, Ducreux M, Goere D, Nguyen F, Malka D. *Eur J Cancer*. 2017 Apr;75:231-242. doi: 10.1016/j.ejca.2017.01.010. Epub 2017 Feb 24. Review.

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM. *J Hepatol*. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.

Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer. Vychnevskaja K, Dumont F, Agostini J, Julié C, Dartigues P, Lazure T, Boige V, Goéré D, Brouquet A, Penna C, Peschaud F, Benoist S. *Ann Surg Oncol*. 2017 May;24(5):1304-1311. doi: 10.1245/s10434-016-5736-8. Epub 2016 Dec 22.

Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded). de Baere T, Tselikas L, Boige V, Ducreux M, Malka D, Goéré D, Benahim E, Deschamps F. *Bull Cancer*. 2017 May;104(5):402-406. doi: 10.1016/j.bulcan.2016.10.025. Epub 2016 Dec 16. Review.

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinssignon V, Paci A, Mir O. *Invest New Drugs*. 2017 Apr;35(2):247-249. doi: 10.1007/s10637-016-0405-0. Epub 2016 Nov 12.

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F; ARTBC International. *Eur J Cancer*. 2016 Nov;68:163-172. doi: 10.1016/j.ejca.2016.09.011. Epub 2016 Oct 18.

Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. Mary F, Zaanen A, Boige V, Artru P, Samalin E, Coriat R, Bachet JB, Boubaya M, Benallaoua M, Tougeron D, Afchain P, Locher C, Baumgaertner I, Lecaillon C, des Guets G, Aparicio T; AGEO (Association des Gastro-Entérologues Oncologues). *Dig Liver Dis*. 2016 Dec;48(12):1498-1502. doi: 10.1016/j.dld.2016.07.022. Epub 2016 Aug 9.

Women at a Disadvantage in Fluorouracil Treatment-Reply. Boige V, Vincent M, Laurent-Puig P. *JAMA Oncol*. 2016 Jun 1;2(6):830-1. doi: 10.1001/jamaoncol.2016.1089. No abstract available.

Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic

Options: A Real-Life Retrospective Study. Berdelou A, Boige V, Arfi-Rouche J, Malka D, Ederhy S, Izzedine H, Leboulleux S, Chougnnet CN, Burtin P, De Baere T, Laplanche A, Elias D, Schlumberger M, Scoazec JY, Ducreux M, Baudin E. *Neuroendocrinology*. 2017;105(1):26-34. doi: 10.1159/000446988. Epub 2016 May 26.

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes? de Baere T, Tselikas L, Deschamps F, Boige V, Ducreux M, Hollebecque A. *Hepat Oncol*. 2016 Apr;3(2):109-118. doi: 10.2217/hep-2015-0001. Epub 2016 Mar 23. Review.

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P. *JAMA Oncol*. 2016 May 1;2(5):655-662. doi: 10.1001/jamaoncol.2015.5392.

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, Innominato P, Ajavon Y, Truant S, Castaing D, De Baere T, Kunstlinger F, Bouchahda M, Afshar M, Rougier P, Adam R, Ducreux M; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International). *Ann Oncol*. 2016 Feb;27(2):267-74. doi: 10.1093/annonc/mdv548. Epub 2015 Nov 16.

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G. *Science*. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29. The consensus molecular subtypes of colorectal cancer. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. *Nat Med*. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussière J. *Ann Oncol*. 2015 Oct;26(10):2196-7. doi: 10.1093/annonc/mdv301. Epub 2015 Jul 20. No abstract available.

Interventional oncology for liver and lung metastases from colorectal cancer: The current state of the art. de Baere T, Tselikas L, Pearson E, Yevitch S, Boige V, Malka D, Ducreux M, Goere D, Elias D, Nguyen F, Deschamps F. *Diagn Interv Imaging*. 2015 Jun;96(6):647-54. doi: 10.1016/j.diii.2015.04.004. Epub 2015 May 16.

Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Gérard JP, Chamorey E, Gourgou-Bourgade S, Benezery K, de Laroche G, Mahé MA, Boige V, Juzyna B. *Radiother Oncol*. 2015 May;115(2):246-52. doi: 10.1016/j.radonc.2015.04.003. Epub 2015 Apr 24.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Lorient Y, Duvillard P, Chougnnet CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E. *Endocr Relat Cancer*. 2015 Jun;22(3):289-98. doi: 10.1530/ERC-15-0075. Epub 2015 Mar 13.

Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussière J. *Ann Oncol*. 2015 May;26(5):987-91. doi: 10.1093/annonc/mdv037. Epub 2015 Feb 16.

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802). Aparicio T, Linot B, Le Malicot K, Bouché O, Boige V, François E, Ghiringhelli F, Legoux JL, Ben Abdelghani M, Phelip JM, Faroux R, Dahan L, Taieb J, Bedenne L. *Dig Liver Dis*. 2015 Apr;47(4):271-2. doi: 10.1016/j.dld.2015.01.146. Epub 2015 Jan 20. No abstract available.

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Manceau G, Marisa L, Boige V, Duval A, Gaub MP, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, Lecorre D, Guenot D, Etienne-Grimaldi MC, Kirzin S, Martin L, Lepage C, Bouvier AM, Laurent-Puig P. *Cancer Med*. 2015 Mar;4(3):371-82. doi: 10.1002/cam4.370. Epub 2015 Feb 2.

Systemic treatment of advanced hepatocellular carcinoma: from disillusion to new horizons. Hollebecque A, Malka D, Fertié C, Ducreux M, **Boige V**. *Eur J Cancer*. 2015 Feb;51(3):327-39. doi: 10.1016/j.ejca.2014.12.005. Epub 2015 Jan 2. Review.

Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Allard MA, Sebah M, Baillie G, Lemoine A, Dartigues P, Faitot F, Faron M, Boige V, Vitadello F, Vibert E, Elias D, Adam R, Goéré D, Sa Cunha A. *Ann Surg Oncol*. 2015;22(6):1925-32. doi: 10.1245/s10434-014-4272-7. Epub 2014 Dec 2.

Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Robb WB, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF, Mariette C; Fédération Française de Cancérologie Digestive, Société Française de Radiothérapie Oncologique, Union des Centres de Lutte Contre le Cancer, Groupe Coopérateur Multidisciplinaire en Oncologie, French EsoGAstic Tumour working group, Fédération de Recherche En Chirurgie. *Ann Surg*. 2015 May;261(5):902-8. doi: 10.1097/SLA.0000000000000991.

Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor T, El Harrak Z, Li X, Link DR, Bouché O, Emile JF, Landi B, Boige V, Hutchison JB, Taly V. *Clin Cancer Res*. 2015 Mar 1;21(5):1087-97. doi: 10.1158/1078-0432.CCR-14-0983. Epub 2014 Sep 23.50.

Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial. Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, Peiffert D, Mornex F, Abbas M, Boige V, Pignon JP, Conroy T, Cellier P, Juzyna B, Viret F. *Dig Liver Dis*. 2014 Oct;46(10):950-5. doi: 10.1016/j.dld.2014.06.006. Epub 2014 Jul 12.

Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF. *J Clin Oncol*. 2014 Aug 10;32(23):2416-22. doi: 10.1200/JCO.2013.53.6532. Epub 2014 Jun 30.

Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, Boige V, Malka D, Leboulleux S, Ducreux M, Baudin E, Deschamps F. *Cardiovasc Intervent Radiol*. 2015 Apr;38(2):372-80. doi: 10.1007/s00270-014-0914-1. Epub 2014 May 30.

Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. Etienne-Grimaldi MC, Mahamat A, Chazal M, Laurent-Puig P, Olschwang S, Gaub MP, Formento JL, Formento P, Sudaka A, Boige V, Abderrahim-Ferkoune A, Benchimol D, André T, Houry S, Faucheron JL, Letoublon C, Gilly FN, Delpero JR, Lasser P, Pradere B, Pezet D, Penault-Llorca F, Milano G. *Br J Cancer*. 2014 May 27;110(11):2728-37. doi: 10.1038/bjc.2014.213. Epub 2014 May 6.

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Manceau G, Imbeaud S, Thiébaud R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL,

Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P. Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25.

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, **Boige V**. Invest New Drugs. 2014 Oct;32(5):1028-35. doi: 10.1007/s10637-014-0100-y. Epub 2014 Apr 22.

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJ, Redman MW, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ. Pharmacogenomics J. 2014 Oct;14(5):424-31. doi: 10.1038/tpj.2014.16. Epub 2014 Apr 8.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. J Clin Oncol. 2014 Apr 1;32(10):1031-9. doi: 10.1200/JCO.2013.51.1857. Epub 2014 Mar 3. Review.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.

A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Elias D, Faron M, Goéré D, Dumont F, Honoré C, Boige V, Malka D, Ducreux M. Ann Surg Oncol. 2014 Jun;21(6):2052-8. doi: 10.1245/s10434-014-3506-z. Epub 2014 Feb 6.

Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, Malka D, Boige V, Ducreux M. Eur J Cancer. 2014 Jan;50(2):332-40. doi: 10.1016/j.ejca.2013.09.024. Epub 2013 Oct 21. Review.

Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers. Elias D, Borget I, Farron M, Dromain C, Ducreux M, Goéré D, Honoré C, Boige V, Dumont F, Malka D, Pottier E, Caramella C. Eur J Surg Oncol. 2013 Nov;39(11):1214-8. doi: 10.1016/j.ejso.2013.08.006. Epub 2013 Sep 14.

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26.

Value of cardiophrenic angle lymph node for the diagnosis of colorectal peritoneal carcinomatosis. Caramella C, Pottier E, Borget I, Malka D, Goéré D, Boige V, Honoré C, Dartigues P, Dumont F, Ducreux M, Elias D, Dromain C. Eur J Cancer. 2013 Dec;49(18):3798-805. doi: 10.1016/j.ejca.2013.06.044. Epub 2013 Jul 27.

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Chaput N, Svrcek M, Aupérin A, Locher C, Drusch F, Malka D, Taïeb J, Goéré D, Ducreux M, **Boige V**. Br J Cancer. 2013 Aug 20;109(4):1013-22. doi: 10.1038/bjc.2013.362. Epub 2013 Jul 18.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, **Boige V**. PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

Placement of an arterial hepatic catheter after a major hepatectomy for colorectal liver metastases: is this safe? Benhaim L, Goéré D, Deschamps F, Dumont F, Bonnet S, Honoré C, Malka D, Boige V, De Baere T, Elias D. Eur J Surg Oncol. 2013 Jun;39(6):640-7. doi: 10.1016/j.ejso.2013.02.002. Epub 2013 Mar 13.

Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D. Ann Surg. 2013 Jun;257(6):1065-71. doi: 10.1097/SLA.0b013e31827e9289.

Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Goéré D, Benhaim L, Bonnet S, Malka D, Faron M, Elias D, Lefèvre JH, Deschamps F, Dromain C, Boige V, Dumont F, De Baere T, Ducreux M. Ann Surg. 2013 Jan;257(1):114-20. doi: 10.1097/SLA.0b013e31827b9005.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. J Clin Oncol. 2013 Jan 1;31(1):23-9. doi: 10.1200/JCO.2012.44.4869. Epub 2012 Dec 3.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. Zaanen A, Williet N, Hebbbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattani S, Bonnetain F, Boige V, Taïeb J. J Hepatol. 2013 Jan;58(1):81-8. doi: 10.1016/j.jhep.2012.09.006. Epub 2012 Sep 16.

Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. Ferrand F, Malka D, Bourredjem A, Allonier C, Bouché O, Louafi S, Boige V, Mousseau M, Raoul JL, Bedenne L, Leduc B, Deguiral P, Faron M, Pignon JP, Ducreux M. Eur J Cancer. 2013 Jan;49(1):90-7. doi: 10.1016/j.ejca.2012.07.006. Epub 2012 Aug 25.

Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Fortea N, De Baere T, Ducreux M, Farace F. Oncologist. 2012;17(8):1063-72. doi: 10.1634/theoncologist.2011-0465. Epub 2012 Jun 15.

Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Gras P, Truant S, Boige V, Ladrat L, Rougier P, Pruvot FR, Hebbbar M. Case Rep Oncol. 2012 Jan;5(1):169-72. doi: 10.1159/000338242. Epub 2012 Apr 3.

Central retroperitoneal recurrences from colorectal cancer: are lymph node and locoregional recurrences the same disease? Dumont F, Kothodinis K, Goéré D, Honoré C, Dartigues P, Boige V, Ducreux M, Malka D, Elias D. Eur J Surg Oncol. 2012 Jul;38(7):611-6. doi: 10.1016/j.ejso.2012.04.003. Epub 2012 Apr 21.

Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. Chu C, Noël-Hudson MS, Boige V, Goéré D, Marion S, Polrot M, Bigot L, Gonin P, Farinotti R, Bonhomme-Faivre L. Fundam Clin Pharmacol. 2013 Aug;27(4):434-42. doi: 10.1111/j.1472-8206.2012.01035.x. Epub 2012 Mar 28.

Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations? Laurent-Puig P, Manceau G, Boige V, Blons H. Gut. 2012 May;61(5):637-8. doi: 10.1136/gutjnl-2011-301767. Epub 2011 Dec 26. No abstract available.

Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, Malka D, Leboulleux S, Ducreux M, Schlumberger M, Baudin E, de Baere T. *J Hepatol*. 2012 Mar;56(3):609-17. doi: 10.1016/j.jhep.2011.09.012. Epub 2011 Oct 23.

Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Guiu B, Deschamps F, Boulin M, Boige V, Malka D, Ducreux M, Hillon P, de Baère T. *Cardiovasc Intervent Radiol*. 2012 Oct;35(5):1102-8. Epub 2011 Oct 19.

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouché O; Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group. *Lancet Oncol*. 2011 Oct;12(11):1032-44. doi: 10.1016/S1470-2045(11)70199-1. Epub 2011 Sep 6.

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, François E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F. *Ann Oncol*. 2012 Apr;23(4):919-27. doi: 10.1093/annonc/mdr365. Epub 2011 Aug 8.

Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Elias D, Honoré C, Dumont F, Ducreux M, Boige V, Malka D, Burtin P, Dromain C, Goéré D. *Ann Surg*. 2011 Aug;254(2):289-93. doi: 10.1097/SLA.0b013e31822638f6.

Disseminated and circulating tumor cells in gastrointestinal oncology. Bidard FC, Ferrand FR, Huguet F, Hammel P, Louvet C, Malka D, Boige V, Ducreux M, Andre T, de Gramont A, Mariani P, Pierga JY. *Crit Rev Oncol Hematol*. 2012 May;82(2):103-15. doi: 10.1016/j.critrevonc.2011.05.008. Epub 2011 Jun 15. Review.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. *J Clin Oncol*. 2011 May 1;29(13):1715-21. doi: 10.1200/JCO.2010.33.0597. Epub 2011 Mar 28.

[New perspectives for radiosensitization in hepatocellular carcinoma: a review of mechanisms involved in liver oncogenesis]. Chargari C, Boige V, Deutsch E. *Cancer Radiother*. 2011 Feb;15(1):32-8. doi: 10.1016/j.canrad.2010.11.008. Epub 2011 Jan 14. Review. French.

Biliary cancers, chemotherapy, and cetuximab. Malka D, Boige V, Ducreux M. *Lancet Oncol*. 2010 Dec;11(12):1110-2. doi: 10.1016/S1470-2045(10)70267-9. No abstract available.

Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. Deschamps F, Rao P, Teriitehau C, Hakime A, Malka D, Boige V, Ducreux M, Elias D, Goere D, de Baere T. *J Vasc Interv Radiol*. 2010 Nov;21(11):1681-8. doi: 10.1016/j.jvir.2010.08.003.

Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Lassau N, Koscielny S, Chami L, Chebil M, Benatsou B, Roche A, Ducreux M, Malka D, **Boige V**. *Radiology*. 2011 Jan;258(1):291-300. doi: 10.1148/radiol.10091870. Epub 2010 Oct 27.

Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of port-catheters. Deschamps F, Elias D, Goere D, Malka D, Ducreux M, Boige V, Auperin A, de Baere T. *Cardiovasc Intervent Radiol*. 2011 Oct;34(5):973-9. doi: 10.1007/s00270-010-9996-6. Epub 2010 Oct 9.

Lymph road mapping obtained via blue sentinel node detection to avoid middle colic artery resection for highly selected colon cancer cases: proof of a concept? Lo Dico R, Lasser P, Goéré D, Malka D, Boige V, Pocard M. *Tech Coloproctol*. 2010

Sep;14(3):237-40. doi: 10.1007/s10151-010-0603-2. Epub 2010 Jul 15.

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Boige V, Mendiboure J, Pignon JP, Lorient MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P. *J Clin Oncol*. 2010 May 20;28(15):2556-64. doi: 10.1200/JCO.2009.25.2106. Epub 2010 Apr 12.

Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Goéré D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, Dromain C, Ducreux M, Elias D. *Ann Surg*. 2010 Apr;251(4):686-91. doi: 10.1097/SLA.0b013e3181d35983.

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Perkins G, Lièvre A, Ramacci C, Méatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouché O, Penault-Llorca F, Merlin JL, Laurent-Puig P. *Int J Cancer*. 2010 Sep 1;127(6):1321-31. doi: 10.1002/ijc.25152.